Spots Global Cancer Trial Database for Phase I/II Study of Pazopanib and Cyclophosphamide in Patients With Platinum-resistant Recurrent Ovarian Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Phase I/II Study of Pazopanib and Cyclophosphamide in Patients With Platinum-resistant Recurrent Ovarian Cancer
Official Title: A Phase I/II Study of Pazopanib (GW786034) and Cyclophosphamide in Patients With Platinum-resistant Recurrent, Pre-treated Ovarian Cancer
Study ID: NCT01238770
Conditions
Interventions
Study Description
Brief Summary: The current trial shall clarify the potential of the multitarget antiangiogenic tyrosinkinase inhibitor GW 786034 (pazopanib) in combination with oral cyclophosphamide as salvage treatment in patients with recurrent, pretreated ovarian cancer.
Detailed Description: This study is a prospective open-label, non-randomized multicenter phase I/II trial in order to determine overall response rate of patients with platinum-resistant or refractory recurrent, pretreated epithelial ovarian cancer. In order to assure adequate toxicity assessment, a phase-I-trial is proponed. Phase II will be performed with MTD.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
Marienkrankenhaus Hamburg, Hamburg, , Germany
Universitäts-Frauenklinik, Heidelberg, , Germany
Klinikum Konstanz Gynäkologie und Geburtshilfe, Konstanz, , Germany
Universitätsmedizin der Johannes Gutenberg-Universität Mainz Klinik und Poliklinik fßr Geburtshilfe und Frauenheilkunde, Mainz, , Germany
Universitätsfrauenklinik Tßbingen Klinik fßr Gynäkologie und Geburtshilfe, Tßbingen, , Germany
Contact Details
Name: Michael Eichbaum, PD Dr. med.
Affiliation: Medizinische Fakultät Heidelberg Abteilung fßr Frauenheilkunde und Geburtshilfe
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
